Insider · CIK 0001744425

Esposito Pamela

Reports to the SEC for 2 companies · WATERTOWN, MA

sec.gov

Transactions

Companies

Filings

CIK

0001744425

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-24	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+6,068 sh	—	—	6,068
2026-05-19	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,000 sh	$31.20	+$31.2K	1,000
2026-05-19	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,000 sh	—	—	9,000
2026-03-20	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,500 sh	$49.10	+$123K	2,500
2026-03-20	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−700 sh	$77.71	−$54.4K	1,800
2026-03-20	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−600 sh	$79.24	−$47.5K	1,200
2026-03-20	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−1,200 sh	$79.94	−$95.9K	0
2026-03-20	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,500 sh	—	—	0
2026-02-20	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,500 sh	$49.10	+$123K	2,500
2026-02-20	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−1,900 sh	$87.06	−$165K	600
2026-02-20	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−600 sh	$88.10	−$52.9K	0
2026-02-20	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,500 sh	—	—	2,500
2026-01-20	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,000 sh	$31.20	+$93.6K	3,000
2026-01-20	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,500 sh	$49.10	+$123K	5,500
2026-01-20	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−400 sh	$66.68	−$26.7K	5,100
2026-01-20	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−4,900 sh	$67.99	−$333K	200
2026-01-20	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−200 sh	$68.52	−$13.7K	0
2026-01-20	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,000 sh	—	—	10,000
2026-01-20	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,500 sh	—	—	5,000
2025-12-17	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+12.6K sh	$49.10	+$617K	12,563
2025-12-17	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+12K sh	$27.67	+$332K	24,563
2025-12-17	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,000 sh	$31.20	+$93.6K	27,563
2025-12-17	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−14.5K sh	$81.56	−$1.18M	13,058
2025-12-17	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−7,959 sh	$82.34	−$655K	5,099
2025-12-17	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−4,099 sh	$83.45	−$342K	1,000
2025-12-17	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−1,000 sh	$84.07	−$84.1K	0
2025-12-17	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−12.6K sh	—	—	7,500
2025-12-17	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−12K sh	—	—	0
2025-12-17	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,000 sh	—	—	13,000
2025-06-25	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+16K sh	—	—	16,000
2025-06-03	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+5,000 sh	$29.55	+$148K	5,000
2025-06-03	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−5,000 sh	$49.04	−$245K	0
2025-06-03	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−5,000 sh	—	—	24,127
2024-12-02	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,500 sh	$29.55	+$73.9K	2,500
2024-12-02	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−2,500 sh	$49.00	−$123K	0
2024-12-02	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,500 sh	—	—	29,127
2024-09-17	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+8,500 sh	$29.55	+$251K	8,500
2024-09-17	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+5,000 sh	$14.18	+$70.9K	13,500
2024-09-17	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−6,350 sh	$47.75	−$303K	7,150
2024-09-17	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−7,150 sh	$48.75	−$349K	0
2024-09-17	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−8,500 sh	—	—	31,627
2024-09-17	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−5,000 sh	—	—	7,000
2024-06-18	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+16K sh	—	—	16,000
2023-09-12	REPLReplimune Group, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+300 sh	$3.30	+$990	263,736
2023-09-12	REPLReplimune Group, Inc.S Sale	Chief Business Officer	SSale	−300 sh	$20.00	−$6,000	263,436
2023-09-12	REPLReplimune Group, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−300 sh	—	—	86,033
2023-09-11	REPLReplimune Group, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+5,358 sh	$3.30	+$17.7K	268,794
2023-09-11	REPLReplimune Group, Inc.S Sale	Chief Business Officer	SSale	−5,358 sh	$20.01	−$107K	263,436
2023-09-11	REPLReplimune Group, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−5,358 sh	—	—	86,333
2023-08-22	REPLReplimune Group, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+13.6K sh	$3.30	+$44.9K	277,036

Recent filings

Accepted (ET)
Jun 254
Esposito Pamela0001193125-26-283134
SEC(opens sec.gov)
May 194
Esposito Pamela0001193125-26-230730
SEC(opens sec.gov)
Mar 204
Esposito Pamela0001193125-26-118032
SEC(opens sec.gov)
Feb 204
Esposito Pamela0001193125-26-061686
SEC(opens sec.gov)
Jan 204
Esposito Pamela0001193125-26-016934
SEC(opens sec.gov)
Dec 174
Esposito Pamela0001193125-25-323090
SEC(opens sec.gov)

Companies

Address

C/O KYMERA THERAPEUTICS, INC. 500 NORTH BEACON STREET, 4TH FLOOR

WATERTOWN, MA, 02472